克唑替尼二线治疗晚期非小细胞肺癌的成本效果分析

Cost-effectiveness Analysis of Crizotinib Using in Advanced NSCLC

目的对克唑替尼二线用于晚期非小细胞肺癌进行成本效果分析,为临床合理用药提供参考。方法文献荟萃法获取克唑替尼二线治疗晚期非小细胞肺癌的效果,依照某肿瘤医院的收费标准,建立晚期非小细胞肺癌治疗的成本模型,综合进行成本-效果分析,得出结论。结果克唑替尼组、培美曲塞组、多西他赛组有效率分别是66%、29%及7%,中位无进展生存期分别是7.7,4.2,2.6个月,治疗总成本分别为214 000.8、121 645.7、36 979.96元,C/E分别是3 242.4、4 194.8、5 282.8,以多西他赛组为参照,培美曲塞和克唑替尼组ΔC/ΔE值分别为3 000.3、3 848.4。结论克唑替尼二线治疗晚期非小细胞肺癌相对化疗组有经济学优势。

OBJECTIVE To analyze the cost-effectiveness of crizotinib in advanced alk-positive NSCLC,and provide reference for clinical rational drug use. METHODS Therapeutic effects data were collected by using data from published literatures,costs were estimated according to the standards of certain tumor hospital,comprehensive cost-effectiveness analysis were performed. RESULTS The effective rates of crizotinib,pemetrexed and docetaxel were 66%,29% and 7%,respectively. The median progression-free survivals were 7.7,4. 2,2. 6 months,respectively. The total treatment cost of each group were 214 000. 8,121 645. 7 and 36 979. 96 yuan,respectively.The C/E of each group were 3 242.4,4 194.8 and 5 282.8,taking docetaxel group as reference,the ΔC/ΔE of pemetrexed and crizotinib groups were 3 000.3 and 3 848.4,respectively. CONCLUSION Crizotinib is cost-effective in the treatment of advanced ALK-positive NSCLC compared with chemotherapy.